Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 10/20 | 0.45 |
| ▸ | CA1 | P00915 | 9/20 | 0.42 |
| ▸ | CA9 | Q16790 | 5/20 | 0.42 |
| ▸ | CA12 | O43570 | 3/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 3/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.41 |
| ▸ | CA4 | P22748 | 2/20 | 0.41 |
| ▸ | KDR | P35968 | 1/20 | 0.41 |
| ▸ | CA7 | P43166 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10059717 | 0.92 | TOP2A (0.40) | CA2MAPTALDH1A1MEN1KMT2A | |
| SCHEMBL16474864 | 0.90 | CA2 (0.47) | CA2CA1CA9CA12MAPT | |
| SCHEMBL10059697 | 0.90 | SMN1; SMN2 (0.47) | MAPTALDH1A1KDM4EMEN1KMT2A | |
| SCHEMBL19942386 | 0.88 | PLAU (0.36) | CA2MAPTALDH1A1MEN1KMT2A | |
| SCHEMBL17612683 | 0.87 | NPC1 (0.44) | CA2CA1CA9CA12MAPT | |
| SCHEMBL16474863 | 0.87 | EPHX2 (0.41) | CA2MAPTALDH1A1KDM4EMEN1 | |
| SCHEMBL10059698 | 0.87 | ALDH1A1 (0.46) | MAPTALDH1A1MEN1KMT2ALMNA | |
| SCHEMBL10059725 | 0.87 | MAPT (0.50) | CA2CA1CA9CA12MAPT | |
| SCHEMBL16474824 | 0.87 | CA1 (0.50) | CA2CA1CA9CA12MEN1 | |
| SCHEMBL21249142 | 0.86 | POLB (0.44) | MAPTALDH1A1KDM4EMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9290450-B2 | Compounds and methods for treating inflammatory and fibrotic disorders | INTERMUNE, INC. (US) | 2016-03-22 | — | — | US | disclosed |
| US-8969347-B2 | Compounds and methods for treating inflammatory and fibrotic disorders | INTERMUNE, INC. | 2015-03-03 | — | — | US | disclosed |
| US-20130102597-A1 | COMPOUNDS AND METHODS FOR TREATING INFLAMMATORY AND FIBROTIC DISORDERS | INTERMUNE, INC. (US) | 2013-04-25 | — | — | US | disclosed |
| US-20120014917-A1 | METHODS OF TREATING HIV PATIENTS WITH ANTI-FIBROTICS | UNIVERSITY OF MINNESOTA (US) | 2012-01-19 | — | — | US | disclosed |
| US-20110218515-A1 | Methods for Treating Acute Myocardial Infarctions and Associated Disorders | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2011-09-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130102597-A1 | COMPOUNDS AND METHODS FOR TREATING INFLAMMATORY AND FIBROTIC DISORDERS | MAP3K8, MAP3K1, MAP3K6 | CA2 4364/4885CA1 4695/4885CA9 4755/4885 |
| US-20120014917-A1 | METHODS OF TREATING HIV PATIENTS WITH ANTI-FIBROTICS | MMP1, MMP8, CCL11 | CA2 4060/4885CA1 4642/4885CA9 4123/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.